Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/29305
Title: Survival benefits of antiretroviral therapy in Brazil: a model-based analysis
Authors: Luz, Paula M.
Girouard, Michael P.
Grinsztejn, Beatriz
Freedberg, Kenneth A.
Veloso, Valdilea G.
Losina, Elena
Struchiner, Claudio J.
MacLean, Rachel L.
Parker, Robert A.
Paltiel, A. David
Walensky, Rochelle P.
Affilliation: Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA./ Division of Infectious Disease, Massachusetts General Hospital Boston, MA, USA./ Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA./ Department of Epidemiology, Boston University School of Public Health Boston, MA, USA./ Department of Health Policy and Management, Harvard School of Public Health Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA./ Department of Orthopedic Surgery, Brigham and Women's Hospital Boston, MA, USA./ Department of Biostatistics, Boston University School of Public Health Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA.
Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA./ Biostatistics Center, Massachusetts General Hospital Boston, MA, USA.
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
Medical Practice Evaluation Center, Massachusetts General Hospital Boston, MA, USA./ Division of General Internal Medicine, Massachusetts General Hospital Boston, MA, USA./ Division of Infectious Disease, Massachusetts General Hospital Boston, MA, USA./ Harvard University Center for AIDS Research, Harvard Medical School Boston, MA, USA./ Division of Infectious Disease, Brigham and Women's Hospital Boston, MA, USA.
Abstract: In Brazil, universal provision of antiretroviral therapy (ART) has been guaranteed free of charge to eligible HIV-positive patients since December 1996. We sought to quantify the survival benefits of ART attributable to this programme.
Keywords: Brazil
HIV
Latin America
Highly active antiretroviral therapy
Modelling
Survival
Issue Date: 2016
Citation: LUZ, P. M. et al. Survival Benefits of Antiretroviral Therapy in Brazil: A Model-Based Analysis. Journal of the International AIDS Society, v. 19, n. 1, p. 20623, 2016
DOI: 10.7448/IAS.19.1.20623
ISSN: 1758-2652
Copyright: open access
Appears in Collections:INI - Artigos de Periódicos



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.